Genetic Testing

Pharmacogenetic Testing from Merit

For even the most seasoned physician, choosing an effective medication or dose often requires time-consuming and potentially dangerous trial and error. This unfortunate fact is partly due to the role of the patient’s genetic profile in determining how he or she will respond to a particular compound – information that, until recent years, was largely inaccessible to doctors.

What role does Merit play in PGx testing?

Our team of clinical specialists can help your hospital or physicians group establish routine pharmacogenetic testing in your own laboratory. As part of our comprehensive offering, we provide the following services: 

  • Train laboratory personnel in PGx testing protocols
  • Remotely manage the laboratory and provide technical support
  • Deliver fully-validated SOPs
  • Report patient genetic data in a HIPAA-compliant, web-based format
  • Continually monitor PGx research and update clinical guidance to physicians as appropriate
  • Offer customized PGx testing panels where desired, as well as future opportunities to expand genetic offerings into other areas (e.g., disease susceptibility)

What PGx testing can your laboratory perform

Merit helps providers to test their patients for clinically actionable mutations with relevance to various disciplines, including pain management, cardiology, and psychiatry. Clinicians may opt to use a menu of individual tests, consisting of mutations from 16 distinct drug metabolism genes, transporters, and coagulation factors (see our complete list below). Alternatively, providers can choose to work directly with Merit consultants to develop a customized panel based on their specific needs.In either case, final test results are delivered in a comprehensive, easy-to-interpret report. Physicians will have secure web-based access to information for each patient that is critical to delivering personalized care: warnings about specific adverse drug reaction risks, dosing guidance (based on metabolizer status), alternative drug recommendations, and drug-drug interactions.

Genes currently tested

CYP2C9 | VKORC1 | CYP2C19 | CYP2D6 | CYP3A4 | CYP3A5 | CYP1A2 | CYP2B6Factor ll | Factor V Leiden | SLCO1B1 | COMT | OPRM1 | APOE | MTHFR | ANKK1/DRD2

Areas of Focus

Cardiology | Pain Management | Psychiatry | Urology | Gastroenterology | Thrombophilia Risk